Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 71 of 106 for:    Recruiting, Not yet recruiting, Available Studies | (idiopathic pulmonary fibrosis)

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03502902
Recruitment Status : Recruiting
First Posted : April 19, 2018
Last Update Posted : September 7, 2018
Sponsor:
Collaborator:
Covance
Information provided by (Responsible Party):
Sunshine Lake Pharma Co., Ltd.

Brief Summary:
A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female Subjects

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: HEC 68498 Drug: Placebo Phase 1

Detailed Description:
Single-dose, sequential-group design incorporating a food-effect evaluation. Each subject will participate in 1 treatment period, except for Group 5, where each subject will participate in 2 treatment periods. In each group, 6 subjects will receive HEC68498 and 2 subjects will receive placebo. Subjects in Group 5 will receive the same dose level of HEC68498 (or placebo) in both treatment periods. All doses will be administered either after an overnight fast of at least 8 hours or, for subjects in the food-effect evaluation, approximately 30 minutes after starting a standard high-fat breakfast. The first 2 subjects in each group will be dosed (1 subject receiving HEC68498 and 1 subject receiving placebo) 48 hours prior to the remainder of the subjects. There will be a minimum of 7 days between dose escalations. The washout period for subjects in Group 5 will be determined following review of available PK data.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: HEC68498 - A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female Subjects
Actual Study Start Date : May 22, 2018
Estimated Primary Completion Date : January 19, 2019
Estimated Study Completion Date : March 4, 2019


Arm Intervention/treatment
Experimental: HEC68498
administered once on first day in each Treatment Period, HEC68498 VS placebo 3:1 ratio
Drug: HEC 68498
HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.

Placebo Comparator: placebo
administered once on first day in each Treatment Period
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Adverse event [ Time Frame: up to 4 weeks ]
    To assess the safety and tolerability of single dose administered


Secondary Outcome Measures :
  1. AUC0-∞ [ Time Frame: up to one week ]
    area under the concentration versus time curve (AUC) from time zero to infinity

  2. AUC0-t [ Time Frame: up to one week ]
    AUC from time zero to the time of the last quantifiable concentration time zero to the time of the last quantifiable concentration

  3. Cmax [ Time Frame: up to one week ]
    maximum observed plasma concentration

  4. tmax [ Time Frame: up to one week ]
    time of the maximum observed plasma concentration

  5. t½ [ Time Frame: up to one week ]
    apparent terminal elimination half-life

  6. Vz/F [ Time Frame: up to one week ]
    apparent volume of distribution



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males or females, of any race, between 18 and 60 years of age, inclusive, at Screening.
  2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, at Screening.
  3. In good health, determined by no clinically significant findings from medical history,physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
  4. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Section 6.6.
  5. Where doses exceed 10 mg or where the maximum systemic exposure for any individual subject is predicted to exceed that at the NOAEL of the male rat, male subjects must be sterile. For the purposes of this study, sterile male subjects will include those who have had a vasectomy performed at least 90 days prior to the screening visit and have documentation of azoospermia. Virile male subjects will include all males that do not meet the definition of sterile.
  6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  2. Fasting blood glucose >110 mg/dL (confirmed with repeat testing).
  3. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  4. History of stomach or intestinal surgery or resection, including cholecystectomy, that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
  5. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
  6. Alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  7. Positive urine drug screen (including cotinine) at Screening or Check-in, or positive alcohol breath test at Check-in.
  8. Positive hepatitis panel and/or positive human immunodeficiency virus test.
  9. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing.
  10. Use or intend to use any prescription or nonprescription medications/products, including St. John抯 wort, vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing,unless deemed acceptable by the Investigator (or designee).
  11. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
  12. Unwilling or unable to abide by the dietary and exercise restrictions .
  13. Receipt of blood products within 2 months prior to Check-in.
  14. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
  15. Poor peripheral venous access.
  16. Have previously completed or withdrawn from this study or any other study investigating HEC68498, and have previously received the investigational product.
  17. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03502902


Contacts
Layout table for location contacts
Contact: Irene Mirkin, MD 608-442-8200 Irene.Mirkin@covance.com

Locations
Layout table for location information
United States, Florida
Covance Clinical Research Unit, Inc. Recruiting
Daytona Beach, Florida, United States, 32117
Contact: Irene Mirkin, MD    608-443-1477      
Sponsors and Collaborators
Sunshine Lake Pharma Co., Ltd.
Covance
Investigators
Layout table for investigator information
Principal Investigator: Irene Mirkin, MD Covance

Layout table for additonal information
Responsible Party: Sunshine Lake Pharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT03502902     History of Changes
Other Study ID Numbers: PCD-DHEC68498-17-001
First Posted: April 19, 2018    Key Record Dates
Last Update Posted: September 7, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial